Department of Bioengineering and Therapeutic Sciences

Update from the Dean - Fall/Winter 2012

Thu Mar 1, 2012

Mary Anne Koda-Kimble, PharmD

Research: growth over past decade from $17.6 to 43.5 million, Apollonio, Roy, Wells, Center for Quantitative Pharmacology, Quantitative Biosciences Consortium. Faculty: DeGrado, Savic, James, Day, Rice, MacDougall, Fischbach, Huang. Students: Hluhanich, Frear, Gavrilova, Gayle, Tantipinichwong,...

Colleagues respond to Dean Koda-Kimble’s retirement announcement

Tue Jan 24, 2012

Mary Anne Koda-Kimble

Following the UCSF website's announcement of School of Pharmacy Dean Mary Anne Koda-Kimble's June 30, 2012 retirement came

Dean Koda-Kimble announces retirement

Tue Jan 10, 2012

UCSF School of Pharmacy Dean Mary Anne Koda-Kimble, PharmD, announced today that she is stepping down as dean and retiring from UCSF on June 30, 2012, after 14 years as dean and 41 years as a member of the faculty.

Computer models to predict drug clearance by liver cells show promise

Tue Nov 22, 2011

A schematic diagram of the mechanisms built into each cell in the in silico hepatocyte cultures. Checkmarks indicate events affected by the physical and chemical properties of a specific virtual drug object. For example, depending on such properties a given drug bound to an enzyme can have a different probability of being metabolized or released. (Source: Drug Metab Dispos. 2011 Oct;39(10):p. 1910-20)

A holy grail of drug discovery is to answer key questions about potential new drugs less by experiments in petri dishes and lab animals and more by faster, cheaper engineering efforts using predictive computer models.

Consortium inventing medical devices for children gets new funding

Thu Nov 10, 2011

Shuvo Roy, PhD

A two-year-old, cross-disciplinary effort to invent new medical devices for children, co-founded by bioengineer Shuvo Roy, PhD, has received a two-year $1 million grant from the U.S. Food and Drug Administration (FDA) to expand its work.

Drugs screened for effects on key transporters, risk of dangerous interactions

Tue Nov 8, 2011

UCSF scientists are studying key drug transporters that play roles in drug absorption and elimination. Shown here: OCT2 and others in the membrane of cells in the kidney tubules (at right). The urine collecting tubules interface with capillaries (at left) to remove substances such as medications and environmental toxins from the blood.

To reduce the risk of toxic drug interactions, UCSF's Kathy Giacomini, PhD, and colleagues are screening thousands of prescription drugs, testing how much they inhibit key proteins in kidney and liver cell

Nordberg becomes associate dean, finance and administration

Fri Oct 28, 2011

Michael Nordberg, MPA/HSA

Michael Nordberg, MPA/HSA, is the newly appointed associate dean of administration and finance for the UCSF School of Pharmacy.

In-flight programming features bioartificial kidney

Fri Oct 21, 2011

BriYYZ

, CC BY-SA 2.0

Passengers who travel on American Airlines from September through October 2011 will learn about the surgically implantable bioartificial kidney being developed at UCSF as a permanent solution to end stage renal disease.

Fischbach receives Packard Fellowship

Mon Oct 17, 2011

Michael Fischbach, PhD

Michael Fischbach, PhD, who studies drug-like molecules produced by human gut bacteria, has been awarded one the 16 prestigious 2011 Packard Fellowships in Science and Engineering.

Giacomini cites increasing impact of quantitative pharmacology

Mon Oct 10, 2011

Kathy Giacomini, PhD

Pharmaceutical companies will increasingly apply the predictive modeling of quantitative pharmacology to do more efficient drug development, says Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department

Department of Bioengineering and Therapeutic Sciences

Pages